

Pathology and Laboratory Medicine Clinic Building, K6, Core Lab, E-655 2799 W. Grand Blvd. Detroit, MI 48202 855.916.4DNA (4362)

HEREDITARY CANCER PANELS Part I- REQUISITION

| Required Patient Information | Ordering Physician Information | | | | | |
|---|--|--|--|--|--|--|
| Name: Gender: M F | Name: | | | | | |
| MRN: DOB: _MM/_DD/_YYYYY | Address: | | | | | |
| ICD10 Code(s):/ | City: State: Zip: | | | | | |
| ICD-10 Codes are required for billing. When ordering tests for which reimbursement will be sought, order only those tests that are medically necessary for the diagnosis and treatment of the patient. | Phone: Fax: | | | | | |
| Billing & Collection Information | NPI: | | | | | |
| Patient Demographic/Billing/Insurance Form is required to be submitted with this form. Most genetic testing requires insurance prior authorization. Due to high insurance deductibles and member policy benefits, patients may elect to self-pay. Call for more information (855.916.4362) | | | | | | |
| ☐ Bill Client or Institution Client Name: | Client Code/Number: | | | | | |
| ☐ Bill Insurance Prior authorization or reference number: | | | | | | |
| ☐ Patient Self-Pay Call for pricing and payment options Toll Free | 855.916.4362 | | | | | |
| Patient status at time of collection: 🔲 Inpatient 🔲 Outpatient | Collection date: Collection time: | | | | | |
| Providers are responsible to obtain informed consent, as required by Michigan law, for predictive or pre- | symptomatic genetic tests. Informed Consent form is attached to this requisition, please submit with sample. | | | | | |
| Specimen/Source | | | | | | |
| Peripheral blood in lavender (EDTA) top tube (minimum volume: 3 mL) Specir | nen Stability: Ambient – 72 hours; Refrigerated – 1 week. DO NOT FREEZE | | | | | |
| ☐ Extracted DNA: ONLY ACCEPTED FROM CLIA CERTIFIED LABORATORIES | | | | | | |
| Hereditary Cancer Panels | All tests include pathologist interpretation at a separate, additional charge. | | | | | |
| NGS and Full Deletions/ Duplications on all panels below | | | | | | |
| ☐ Hereditary Colorectal/ HNPCC Cancer Risk Panel (81435, 81436) 15 genes | | | | | | |
| APC, ATM, BMPR1A, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, MUTYI | I, PMS2, PTEN, SMAD4, STK11, TP53 | | | | | |
| Hereditary Endometrial Cancer Risk Panel (81432, 81433) 18 genes | MALITYLI NIDNI DALDO DAGO DTENI DADEAC CTV44 TDEO | | | | | |
| ATM, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, EPCAM, MLH1, MSH2, MSH6, ☐ Hereditary Familial Cutaneous Melanoma Risk Panel (81404) 2 genes | MUTTH, NBN , PALBZ, PMSZ, PTEN, KADSIC , STKII, TP53 | | | | | |
| CDK4, CDKN2A | | | | | | |
| Hereditary Melanoma Panel- Expanded (81162, 81321, 81323, 81351, 81404 | 8 genes | | | | | |
| BAP1, BRCA1, BRCA2, CDK4, CDKN2A, PTEN, RB1, TP53 Hereditary Neuroendocrine Tumor Disorders Risk Panel (81437, 81438) 13 | enes | | | | | |
| FH, MAX, MEN1, NF1, RET, SDHAF2, SDHB, SDHC, SDHD, TMEM127, TSC1, | | | | | | |
| Hereditary Renal/Urinary Tract Cancer Panel (81292, 81295, 81298, 81307, 81317, 81321, 81404x2, 81405x4, 81406, 81407, 81438, G0452) 26 genes | | | | | | |
| BAP1, BUB1B, CDC73, CDKN1C, DICER1, DIS3L2, EPCAM, FH, FLCN, GPC3, MET, MLH1, MSH2, MSH6, PALB2, PMS2, PTEN, SDHB, SDHC, SDHD, SMARCB1, TP53, TSC1, TSC2, VHL, WT1 | | | | | | |
| ☐ Hereditary Multi-Cancer Risk Assessment Panel (81432, 81433, 81435, 8143 | 5, 81437, 81438) 39 genes | | | | | |
| APC, ATM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, EPCAM, FH, KIT, MAX, MEN1, MLH1, MSH2, MSH6, MUTYH, NBN, NF1, | | | | | | |
| PALB2, PMS2, PTEN, RAD51C, RAD51D, RET, SDHAF2, SDHB, SDHC, SDHD, | | | | | | |
| Customized Hereditary Cancer Risk Panel (CPT codes vary by gene. Con ☐ AIP ☐ BRCA2 ☐ CEBPA ☐ EPCAM ☐ FANCA ☐ FANCL | ☐ HRAS ☐ MUTYH ☐ PMS2 ☐ RECQL4 ☐ SDHD ☐ TSC1 | | | | | |
| □ ALK □ BRIP1 □ CEP57 □ ERCC2 □ FANCB □ FANCM | □ KIT □ NBN □ PRF1 □ RET □ SLX4 □ TSC2 | | | | | |
| □ APC □ BUB1B □ CHEK2 □ ERCC3 □ FANCC □ FH | □ MAX □ NF1 □ PRKAR1A □ RHBDF2 □ SMAD4 □ VHL | | | | | |
| □ ATM □ CDC73 □ CYLD □ ERCC4 □ FANCD2 □ FLCN | □ MEN1 □ NF2 □ PTCH1 □ RUNX1 □ SMARCB1 □ WRN | | | | | |
| □ BAP1 □ CDH1 □ DDB2 □ ERCC5 □ FANCE □ GATA2 | □ MET □ NSD1 □ PTEN □ SBDS □ STK11 □ WT1 | | | | | |
| □ BLM □ CDK4 □ DICER1 □ EXT1 □ FANCE □ GPC3 | ☐ MLH1 ☐ PALB2 ☐ RAD51C ☐ SDHAF2 ☐ SUFU ☐ XPA | | | | | |
| □ BMPR1A□ CDKN1C □ DIS3L2 □ EXT2 □ FANCG □ HOXB13 | □ MSH2 □ PHOX2B □ RAD51D □ SDHB □ TMEM127□ XPC | | | | | |
| (G84) | D MCHC D DMC4 D DD4 D CDHC D TDC2 | | | | | |
| □ BRCA1 □ CDKN2A □ EGFR □ EZH2 □ FANCI □ HNF1A | ☐ MSH6 ☐ PMS1 ☐ RB1 ☐ SDHC ☐ TP53 | | | | | |
| Other Test(s) | Send Additional Report To: | | | | | |
| | Name: | | | | | |

Phone #:

Fax #:



UPDATED 7.7.2021

Pathology and Laboratory Medicine Clinic Building, K6, Core Lab, E-655 2799 W. Grand Bvd. Detroit, MI 48202 855.916.4DNA (4362)

HEREDITARY CANCER PANELS Part II- HISTORY

The information below is required to perform Hereditary Cancer testing.

| Required Patient Information | Orde | ering Physicia | n Information |
|---|------------------|----------------------|--|
| Name: Gender: M | F Name: _ | | |
| MRN: DOB:MM/_DD/_YYYY | Y Contact I | Phone Number : | |
| Patient Ethnicity | | | |
| □ Ashkenazi Jewish □ Hispanic, Lating □ Asian ex: Colombian, C ex: Asian Indian, Chinese, Filipino, Japanese, Korean □ Middle Eastern | uban, Mexican/Me | n exican American | □ Native American ex: Aztec, Inuit, Lakota, Navajo, Mayan, Purhepecha, □ Native Hawaiian or Other Pacific Islander ex: Chamorro, Fijian, Marshallese, Native Hawaiian □ Other: |
| Is this treatable, preventable, or neither? | | | |
| Will the results of the ordered test(s) affect treatment? | ☐ Yes | □ No | |
| Has there been any genetic counseling? | ☐ Yes | □ No | |
| Is there a known mutation in the family? | ☐ Yes | □ No | |
| Specify family member name and relationship | | | |
| Gene(s): | Mut | ation(s): | |
| Include lab report and/or testing facility if possible. | | | |
| Does the patient have a personal history of cancer? | ☐ Yes | □ No | |
| Specify type(s): | | Ag | e at Diagnosis: |
| type(s): | | Ag | e at Diagnosis: |
| | | | |
| Is there a family history of cancer? | ☐ Yes | □ No | |
| If checked "Yes", please describe in detail below or attach pe | edigree. | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |
| | | | |



INFORMED CONSENT FOR GENETIC TESTING

| PATIENT LAST NAME: FIRST NAME: MI: | | | | |
|--|---|--|--|--|
| (Please Print) | | | | |
| DATE OF BIRTH: MM/DD/YYYY | PATIENT ID/MRN NUMBER: | | | |
| ORDERING PROVIDER INFORMATION (FULL LAST, | r, GENETIC TESTING REQUESTED FOR: | | | |
| FIRST): Name: | | | | |
| Name. | (name of condition) | | | |
| Phone: | (nume of condition) | | | |
| SAMPLE TYPE | The intended purpose is (check all that apply): | | | |
| SAMPLE ITPE Amniotic fluid | Carrier status | | | |
| Blood | Diagnostic | | | |
| ☐ Cheek swab | Predictive | | | |
| ☐ Chorionic villus sample (CVS) | ☐ Prenatal | | | |
| Skin | - Tie-symptomatic | | | |
| ☐ Tissue block | ☐ Screening ☐ Other | | | |
| □ Other | Other | | | |
| | | | | |
| 1. I have been informed about the nature and the purpose of this genetic testing. | | | | |
| 2. I have received an explanation of the effectiveness and limitations of this genetic testing. | | | | |
| I have discussed the benefits and risks of this genetic test with my physician and/or other health care professional. I understand some genetic tests can involve possible medical, psychological or insurance issues for my family and I. | | | | |
| 4. I understand the meaning of possible test results and have been informed how I will receive the result. | | | | |
| 5. I have been informed that genetic testing can sometimes reveal secondary findings-results that are not related to the purpose of testing. I have discussed with my health care professional if and/or how such results will be shared with me. I understand that it is up to me to decide whether I want secondary results reported back to me and what secondary results I want reported. | | | | |
| 6. If ordered by the ordering provider above, I authorize supplemental genetic testing to further aid in diagnosis, treatment and/or risk evaluation(s). | | | | |
| 7. I have been informed who may have access to my biological sample, and that any leftover sample may be retained by the laboratory. | | | | |
| 8. I have been informed who may have access to my genetic test result, which is part of my confidential medical record. | | | | |
| 9. My questions have been answered to my satisfaction. | | | | |
| 10. I understand that this consent form is intended to be used together with the patient information booklet that contains important information explaining the above eight items. I have read this consent form and understand that I can access the booklet electronically at: https://www.michigan.gov/documents/InformedConsent 69182 7.pdf | | | | |
| 11. I received a copy of this form for my records. | | | | |
| I consent to have a sample taken for genetic testing on the above-named patient for the condition(s) listed above. | | | | |
| | - | | | |
| C: CD | ations on Authorized Decion co | | | |
| | atient or Authorized Designee Date | | | |
| Circle one: Self Parent(s) Legal Guardia | n Durable Power of Attorney for Health Care | | | |
| Print Name of Physician or Authorized Delegee explaining the above information: | | | | |
| Signature of Authorized Person: Date: | | | | |
| | | | | |